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Abstract
Major histocompatibility complex class I chain-related gene A (MICA-129)
dimorphism was investigated in 73 autoimmune diabetes patients (type 1
diabetes and latent autoimmune diabetes in adults) and 75 controls from
Algeria. Only MICA-129 Val allele and MICA-129 Val/Val genotype frequencies
were higher among patients than in the control group. Statistical analysis of
the estimated extended HLA-DR-DQ-MICA haplotypes shown that individual
effects of MICA alleles on HLA-DQ2-DR3-MICA-129 Val/Val and HLA-DQ8-DR4-
MICA-129 Val/Val haplotypes were significantly higher in patients than in the
control groups. These preliminary data might suggest a relevant role of MICA-129
Val/Val single nucleotide polymorphism (weak/weak binders of NKG2D receptor)
in the pathogenesis of T1D and LADA.
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Major histocompatibility complex class I chain-related gene A (MICA-129) dimorphism was investigated in 73 autoimmune dia-
betes patients (type 1 diabetes and latent autoimmune diabetes in adults) and 75 controls from Algeria. Only MICA-129 Val al-
lele andMICA-129 Val/Val genotype frequencies were higher among patients than in the control group. Statistical analysis of the
estimated extended HLA-DR-DQ-MICA haplotypes shown that individual effects of MICA alleles on HLA-DQ2-DR3-MICA-129
Val/Val and HLA-DQ8-DR4-MICA-129 Val/Val haplotypes were significantly higher in patients than in the control groups.
These preliminary data might suggest a relevant role of MICA-129 Val/Val single nucleotide polymorphism (weak/weak binders
of NKG2D receptor) in the pathogenesis of T1D and LADA.
Type 1 diabetes (T1D) is a typical autoimmune disease thatresults from the destruction of insulin-producing cells of the
pancreas; the disease was once thought to be mediated exclusively
by CD4 T cells and is now recognized as one in which autoreac-
tive CD8 T cells play a fundamental pathogenic role (37). The
etiology of T1D is complex and involves both genetic and envi-
ronmental factors which play important roles (7, 11, 12).
A permissive genetic background is required for the develop-
ment of the islet autoimmune process generating antibodies (Ab)
against insulin (IAA), glutamic acid decarboxylase isoform 65
(GADA65-Ab), and protein tyrosine phosphatase (IA2) (6, 39). In
1986, Groop et al. showed that islet cell antibodies identify latent
type 1 diabetes mellitus (T1DM) in patients aged 35 to 75 years at
diagnosis (20). These subclasses of diabetes have been referred to
as latent autoimmune diabetes in adults (LADA). Autoantibodies
to glutamate decarboxylase (GAD65Ab) are the most sensitive
and specific markers for these subgroups of diabetes (39). Auto-
immunity is also assumed to be the major cause of LADA because
this category of diabetes shares biochemical markers of cell-di-
rected autoimmunity with classic type 1 diabetes. LADA is con-
sidered a mild form of type 1 diabetes. “Mild” indicates the fact
that patients with LADA do not by clinical judgment need insulin
from the time of diagnosis. However, within the first few years
after the diagnosis of diabetes, a need for insulin treatment devel-
ops in many patients with LADA (30). However, LADA, like clas-
sic T1D, is associated withHLA class II genes (13, 24). The biolog-
ical function of other genes encoded within this region generated
much interest. Among these genes are the family of major histo-
compatibility complex class I (MHC-I) chain-related genes
(MICA and MICB). MICA protein is encoded by the MICA gene
present on chromosome 6p21.3 in the MHC locus, at 46.4 kb
centromeric to the HLA-B gene. The MICA protein comprises a
transmembrane MHC-I alpha-like chain and is not associated to
the -2-microglobulin and does not bind to peptides (15). The
MICA chain is a stress-induced protein and is expressed on the
basolateral membrane of intestinal epithelium cells and in epithe-
lium-derived tumors (18, 42). The receptor of MICA chain was
identified as NKG2D homodimer. MICA protein is highly poly-
morphic and binds to its NKG2D receptor found on the surface of
natural killer (NK) and CD8  T cells (8, 31).
Considerable polymorphism has been observed so far with 54
alleles of MICA and 16 alleles of MICB (5). Trinucleotide repeat
(GCT) microsatellite polymorphisms, which were found on exon
5 by sequence analysis, encode the transmembrane region of the
MICA protein. A change of the amino acid methionine (Met) to
valine (Val) at position 129 of the ()2-heavy chain domain is in
linkage disequilibrium with other allelic changes and seems to
classify MICA proteins of these alleles into strong and weak bind-
ers of NKG2D receptor, which, in turn, influences effector cell
function (18). MICA molecules were proven to play prominent
roles in immune processes (33). The functional relevance of this
variant in NK and T-cell activation led us to hypothesize that the
type of NKG2D and MICA interaction with either high-affinity
(MICA-129 Met) or low-affinity (MICA-129 Val) alleles favors
chronic inflammation or tumor escape in subjects genetically pre-
disposed to these immune disorders (2, 14). The association of the
HLA complex present on chromosome 6 does not alone explain
the total linkage of the HLA region to T1D, leading to the hypoth-
esis of the probable existence of additional causal genes for im-
mune-related disorders in this region. Studies report that poly-
morphism on the MICA genes could be a potential candidate for
association with T1D and LADA (1, 17, 29, 35, 38). In this study,
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we aimed to study allele polymorphism and the functionally rele-
vant dimorphism (129 Val/Met) of the MICA gene in younger
T1D and LADA patients in the Algerian population.
MATERIALS AND METHODS
Patients and controls. The study was carried out with blood samples
taken from73 unrelated antoimmune diabetes patients with autoimmune
diabetes, positive antibodies against insulin and glutamic acid decarbox-
ylase, and very low C peptide and insulin; the sex ratio was 1.6 (45
males/28 females). Table 1 shows the clinical characteristics of the popu-
lation studied. The patient cohort was collected consecutively upon diag-
nosis by diabetology at the Centre Hospitalier Universitaire Mustapha,
Algeria, with the diagnosis beingmade according to theNational Diabetes
Data Group and American Diabetes Association (ADA) criteria (27). We
divided patients into two different groups on the basis of age at the onset
of the disease: group 1 consisted of 30 juveniles with T1D, 16 to 30 years
old (median age, 21.06 3.69 years), and group 2 consisted of 43 LADA
patients 25 to 40 years old (median age, 39.57 4.68 years). All patients
were on insulin therapy upon hospital discharge and presented with ke-
toacidosis. Case genotypes were compared to 75 healthy unrelated blood
donor volunteers from the same locality; they included 45 males and 30
females with a median age of 45 years. None had a first-degree relative
affected with diabetes or other autoimmune disorder. Nondiabetic con-
trol subjects with no family history of diabetes were selected from the
same geographic area. Informed consent was obtained from both the pa-
tients and the healthy donors.
HLA-DR-DQ and MICA-129 genotyping. Genomic DNA was iso-
lated from EDTA-treated peripheral blood samples using chloroform-
phenol assay. HLA DR and DQ alleles were typed by means of PCR se-
quence-specific priming (PCR-SSP) (low resolution; Dynal, Compiègne,
France), and theMICA-129 polymorphismwas explored at theDNA level
(A-to-G change in exon 3 at nucleotide position 454) as previously de-
scribed using a nested PCR-restriction fragment length polymorphism
(PCR-RFLP) procedure using an automated thermal cycler (9600; Per-
kin-Elmer, Cerus, CA). The MICA gene-specific amplicon was used as a
template in a second round of amplification of its exon 3with each primer
(Table 2). The presence of theMICA-129 Val allele was identified by the
presence of a restriction site for RsaI enzyme (Fig. 1) created by a
deliberately introduced mismatch in the reverse primer (2). For clar-
ity, the explored MICA variants are designated MICA-129 Val and
MICA-129 Met.
Statistical analysis. Statistical analysis was performed using the Com-
pare 2 software, version 1.02 (Chicago, IL). Allele frequencies were calcu-
lated from the observed number of genotypes. The significance of differ-
ences in the allele frequencies between each of three groups was
determinate by Fisher’s exact test. The chi-square testing (with Yates’
correction or Fisher exact test for a lownumber of cases)was used to assess
the differences in frequencies for each risk factor. MICA-129 gene poly-
morphisms will be designated here as the MICA-129 Val or Met allele or
their allelic combination into genotype. The P values were corrected (Pc)
by multiplying the P value by the number of tested alleles at each studied
locus. Findings were considered statistically significant at Pc values of less
than 0.05. The odds ratio (OR) was calculated for each risk factor and is
given with its 95% confidence interval (CI).
RESULTS
MICA amino acid 129 polymorphism. We observed that the
MICA-129 Val allele was significantly more frequent in young
T1D and LADA patients than in the controls (for T1D patients,
78.33% versus 65.33% for the controls, Pc of 0.034, OR of 1.92,
and 95% CI of 0.916 to 4.214; for LADA patients, 82.56% ver-
sus 65.33% for the controls, Pc of 2.2  10
3, OR of 2.51, and
TABLE 1 Clinical characteristics of the study population
Parameter
Value for the group
T1D
(n 30)
LADA
(n 43)
Control
(n 75)
Median age (yrs) 21.06 3.69 39.57 4.68 30 7.9
Median age at diagnosis (yrs) 18.06 3.87 26.32 1.90
Median duration of
diabetes (yrs)
2.6 4.87 3.90 3.23
Insulin dose (U/ml) 16.61 3.55 13.39 3.76 7.78 1.55
C peptide (ng/ml) 0.61 0.06 0.98 0.24 1.57 0.34
Hemoglobin A1c (%) 8.23 1.26 8.5 2.01 6 1.006
BMI (kg/m2)a 22 6.8 25.98 5.62 25.98 5.62
a BMI, body mass index.
TABLE 2 List of MICA primer sequences, their positions, and the sizes of the amplified products
PCR type and primer name Primer sequence Location (position [nt])a Product size (bp)
MICA-specific PCR
MICA-FG 5=-CGTTCTTGTCCCTTTGCCCGTGTGC-3= Intron 1 (6823–6847) 2,201
MICA-RF 5=-GATGCTGCCCCCATTCCCTTCCCAAA-3= Intron 5 (8999–9023)
MICA nested PCR
MICA-FM 5=-GGGTCTGTGAGATCCATGA-3= Exon 3 (350–368) 127
MICA-RMb 5=-TGAGCTCTGGAGGACTGGGGTA-3= Exon 3 (455–476)
a Positions are based on GenBank accession number X92841. nt, nucleotide.
b The exon 3 reverse primer has a deliberately introduced mismatch to create an RsaI restriction site.
FIG 1 PCR-RFLP amplification for the studied MICA-129 gene polymor-
phisms. Lane 1, DNA sizemarker; lane 2, product of PCR 2; lanes 3, 4, 5, 8, and
9, samples frompatients with heterozygousMet/Val alleles; lanes 6, 10, and 11,
samples from patients with homozygous Met/Met alleles; lane 7, sample from
patient with homozygous Val/Val alleles.
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95% CI of 1.266 to 5.18), whereas MICA-129 Met allele was
significantly more frequent in control than in patient groups
(for T1D, 34.67% versus 21.67%, Pc of 0.034, OR of 0.52, and
95% CI of 0.237 to 1.092; for LADA, 34.67% versus 17.44%, Pc
of 2.2 103, OR of 0.40, and 95% CI of 0.193 to 0.79) (Table
3). The analysis of the distribution of the different genotypes
(MICA-129 Met/Met, Met/Val, and Val/Val) between the three
groups revealed that the MICA-129 Val/Val genotype is signif-
icantly associated with juvenile T1D and LADA rather than
with controls (for T1D, 60.00% versus 41.33%, Pc of 0.043, OR
of 2.13, and 95% CI of 0.827 to 5.571; for LADA, 67.44% versus
41.33%, Pc of 3.3  10
3, OR of 2.94, and 95% CI of 1.254 to
7.02). Furthermore, we did not find statistical differences in the
distribution of MICA-129 Val allele and MICA-129 Val/Val
genotype between the young T1D and the LADA patients (Pc
values of 0.334 and 0.342, respectively). However, we noticed
that polymorphism of the MICA-129 Val allele has more risks
for the LADA than the juvenile T1D patients (OR of 2.51 and
1.92, respectively). We found that the MICA-129 Val allele,
which was more frequent in the juvenile T1D and LADA
groups than in the control group (78.33% and 82.56% for T1D
and LADA, respectively, versus 65.33% for the control), may
be the risk factor for T1D and LADA; genotype frequencies
were 36.67% and 30.23% for T1D and LADA, respectively, ver-
sus 48% for the control for the heterozygous MICA-129 Met/
Val, 3.33% and 2.33%, respectively, versus 10.67% for the ho-
mozygous MICA-129 Met/Met, and 60.00% and 67.44%,
respectively, versus 41.33% for the homozygous MICA-129
Val/Val.
To illustrate these results, the prevalence of the estimated
extended DR-DQ-MICA-129 haplotypes was analyzed (Table
4). The frequencies of the haplotypes HLA-DQ2/DR3-MICA-
129 Val/Val and Q8/DR4-MICA-129 Val/Val were significantly
increased in juvenile T1D and LADA patients relative to levels
in the controls: for HLA-DQ2/DR3-MICA-129 Val/Val,
53.33% for T1D versus 9.33% for the control (OR, 11; Pc, 1.3
106; 95% CI, 3.448 to 37.291) and 48.84% for LADA versus
9.33% (Pc, 9.1 10
7; OR, 9.27; 95% CI, 3.194 to 28.845); for
DQ8/DR4-MICA-129 Val/Val, 30.00% for T1D versus 5.33%
for the control (Pc, 5.2 10
4; OR, 7.61; 95% CI, 1.848 to 36.4)
TABLE 3MICA-129 allele and genotype frequencies among T1D juvenile, LADA, and control groups
MICA-129 polymorphism
Distribution analysis by groupa
T1D LADA
Frequency in the
controls (no. [%])
Frequency
(no. [%]) Pc 
2 OR (95% CI)
Frequency
(no. [%]) Pc 
2 OR (95% CI)
Alleles
MICA-129 Val 47 (78.33) 0.034 2.8 1.92 (0.916–4.214) 71 (82.56) 2.2 103 7.152 2.51 (1.266–5.18) 98 (65.33)
MICA-129 Met 13 (21.67) 0.034 2.8 0.52 (0.237–1.092) 15 (17.44) 2.2 103 7.152 0.40 (0.193–0.79) 52 (34.67)
Genotypes
MICA-129 Val/Val 18 (60.00) 0.043 2.297 2.13 (0.827–5.571) 29 (67.44) 3.3 103 6.44 2.94 (1.254–7.02) 31 (41.33)
MICA-129 Met/Val 11 (36.67) 0.151 0.7 0.63 (0.236–1.619) 13 (30.23) 0.031 2.859 0.47 (0.194–1.106 36 (48.00)
MICA-129 Met/Met 1 (3.33) 0.153 0.68 0.29 (0.006–2.345) 1 (2.33) 0.062 1.645 0.20 (0.004–1.594) 8 (10.67)
a Groups consist of 30 T1D and 43 LADA patients and 75 controls. OR, odds ratio; 95% CI, 95% confidence interval. Boldface indicates significant differences in the allele and
genotype frequencies between each of the three groups (Pc 0.05).
TABLE 4MICA alleles and HLA-DR-DQ haplotypes in relation to T1D juvenile, LADA, and control groups
HLA-DR-DQ
haplotype
MICA-129
genotype
Distribution analysis by groupa
LADA (n 43) Juveniles (n 30)
Frequency
(no. [%]) in the
controls (n 75)
Frequency
(no. [%]) Pc OR (95% CI)
Frequency
(no. [%]) Pc OR (95% CI)
DR3 DQ2 Met/Met 1 (2.33) 0.303 1.76 (0.022–140.14) 1 (3.33) 0.201 2.55 (0.031–202.950) 1 (1.33)
Met/Val 10 (23.26) 0.118 1.76 (0.600–5.09) 11 (36.67) 0.007 3.37 (1.117–10.013) 11 (14.67)
Val/Val 21 (48.84) 9.1 107 9.27 (3.194–28.84) 16 (53.33) 1.3 106 11 (3.448–37.291) 7 (9.33)
DR4 DQ8 Met/Met 1 (2.33) 0.303 0.00 (0.015–18.30) 0 (0) 0.0 0(0.0)
Met/Val 5 (11.63) 0.167 1.83 (0.395–8.51) 5 (16.67) 0.057 2.8 (0.584–13.155) 5 (6.67)
Val/Val 15 (34.88) 2.0 105 9.51 (2.665–41.89) 9 (30.00) 5.2 104 7.61 (1.848–36.4) 4 (5.33)
DR15/DQ6 Met/Met 0 (0.0) 0.156 0.0 (0.000–72.56) 0 (0.0) 0.249 0.0 (0.000–6.089) 3 (4)
Met/Val 1 (2.33) 0.041 0.17 (0.004–1.35) 0 (0.0) 0.027 0.0 (0.000–1.207) 9 (12)
Val/Val 6 (13.95) 0.105 0.51 (0.153–1.52) 1 (3.33) 5.4 103 0.11 (0.003–0.772) 18 (24)
Other Met/Met 0 (0) 0.097 0.0 (0.000–1.54) 0 (0.0) 0.174 0.0 (0.000–3.795) 4 (5.33)
Met/Val 6 (13.95) 0.341 0.77 (0.222–2.42) 1 (3.45) 0.032 0.16 (0.004–1.210) 13 (17.33)
Val/Val 10 (23.26) 0.021 2.94 (0.908–9.90) 4 (13.33) 0.239 1.49 (0.294–6.450) 7(9.33)
a OR, odds ratio; CI, confidence interval; Pc, corrected P value. Boldface indicates significant differences in the allele and genotype frequencies between each of the three groups (Pc 0.05).
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and 34.88% for LADA versus 5.33% (OR, 9.51; Pc, 2.0 10
5;
95% CI, 2.665 to 41.896). These haplotypes confer significant
susceptibility to T1D.
DISCUSSION
In previous studies, some authors have hypothesized that MICA
could engage both adaptive and innate immunity (32). In addi-
tion, MICA alleles may also be associated with susceptibility or
resistance to developing autoimmunity (10). Recently, several au-
thors have shown that the MICA-129 polymorphism was associ-
ated with several pathologies (9, 14, 23). In contrast, it has been
demonstrated that a change of methionine to valine at position
129 of the 2-heavy chain domain classifies MICA alleles into
strong (MICA-129 Met) or weak (MICA-129 Val) binders of
NKG2D receptor (33). However, the role of MICA-129 dimor-
phism in T1D susceptibility has not been investigated yet. This
shortcoming has been addressed in this study by investigating
whether MICA-129 dimorphism was associated with susceptibil-
ity to/or resistance against developing T1D. We found that the
MICA-129 Val allele, which was more frequent in the juvenile
T1D and LADA than in the control group, may be a risk factor for
autoimmune diabetes.
That the MICA-129 Met/Val heterozygote and MICA-129
Met/Met homozygote (strong NKG2D binders)were significantly
more prevalent in the control group than in the patient groups
may suggest a beneficial role in healthy individuals and may be
associated with protection against the autoimmune diabetes. It
can be hypothesized that the presence of MICA-129Met/Met and
MICA-129 Met/Val genotypes may modify NK and CD8 T lym-
phocyte activation to mount an adequate immune response,
thereby allowing an immune response to viral infections including
enterovirus, adenovirus, coxsackie B virus, cytomegalovirus, and
hepatitis C virus (26).
Studies performed in different populations showed an associ-
ation of different MICA alleles with type 1 diabetes (1, 29, 36, 38).
In addition, several studies demonstrated the association ofMICA
alleles with the age of the patient presenting the clinical onset of
T1D (16, 21) or an association with LADA (16, 31). In our study
carried out on the Algerian population, the MICA-129 Val allele
was found to be associated with adult-onset T1D (25 years old;
OR of 1.92) and with LADA (25 years old; OR of 2.51). We also
found that a combination of theMICA-129 Val/Val genotype and
DR3-DQ2 or DR4-DQ8 conferred an increased risk for adult-
onset T1D (OR of 11 or 6.45, respectively) and for LADA (OR of
9.27 or 9.51, respectively).
In addition, we provided new evidence of the significant asso-
ciation between the MICA-129 Val allele and adult-onset T1D.
This association was also observed in a patient with LADA, sug-
gesting a common genetic background for LADA and adult-onset
T1D. We have indirectly confirmed the autoimmune origin of
LADA based on our findings of the association between LADA
and MICA-129 gene polymorphisms. These clinical and autoim-
mune markers do vary in the different age categories, supporting
the conclusion that MICA contributes to the disease irrespective
of the autoimmune markers and residual  cell function. These
findings and interpretations were in line with other pathological
contexts (3, 9, 14, 23, 25, 29, 34, 41).
In the context of autoimmune disease, alleles at the MICA lo-
cus can be defined as strong or weak binders to theNKG2D recep-
tor. The strong NKG2D binding alleles share methionine at posi-
tion 129 with high affinity (MICA-129 Met), whereas weak
binding alleles have valine at this position with low affinity (MI-
CA-129 Val). The significance of high/low affinity for the NKG2D
receptor in terms of immune activation is not completely under-
stood yet. However, in this study and in the context of T1D, it can
be hypothesized that the presence of the weak engagement of
NKG2Dreceptors by theweak binderMICA-129Val allele implies
both pathways (14). The ultimate consequence of such weak in-
teraction could be the impairment of natural killer (NK) or cyto-
toxic T lymphocyte cell activation and costimulation, possibly
skewing the Th1 pathway toward Th2, with consequent B cell
activation and Ab production. The weak interaction could lead to
overexpression of NKG2D receptors as previously shown in auto-
immune diseases (19, 22, 28). This situation could favor the bind-
ing of other ligands such as UL-16 and UL-16 binding proteins
(ULBPs) (4). Thus, in a microenvironment highly enriched in
interleukin-15 (IL-15), repeated T and NK stimulation favors an
autoimmune-like situation, breaking down the self-tolerancewith
consequent auto-Ab production. The presence of autoimmunity
against pancreatic  cells in the T1D and LADA group was as-
sessed by detection of autoantibodies in the peripheral blood. It
has been shown that autoantibody production has been detected
up to 5 years prior to the development of hyperglycemic events,
and this indicates that autoantibody production precedes the clin-
ical manifestation of T1D (40).Molecularmimicry is by far one of
the most well studied processes associated with viral triggering
mechanisms and T1D disease induction. Viruses produce pro-
teins similar to those of the host, and certain viral components
share a distinct homology with identified -cell antigens targeted
in an autoimmune response (26).
In conclusion, our findings highlight that the MICA-129 gene
polymorphism is a functionally relevant gene associated with T1D
and LADA and seems to play a potential role in the development
of T1D in the patient population in central Algeria. This study
might provide a better understanding of the implications ofMICA
genetic variation in T1D immunology, thus helping to design fu-
ture detection andmonitoring assays. We are planning additional
work in order to determine the conditional extended transmission
disequilibrium between MICA-129 and HLA class I.
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